Drugmakers expected to spend more on DTC ads this year

03/4/2013 | Pharmalot.com

Eli Lilly & Co.'s antidepressant Cymbalta, Pfizer's pain drug Celebrex and GlaxoSmithKline's chronic obstructive pulmonary disorder drug Advair were the most heavily promoted therapies last year, according to market research firm Cegedim Strategic Data. Overall promotional spending in the U.S. was 8% lower than in 2011, but spending on nervous system, cardiovascular, and alimentary tract and metabolism drugs showed little change. CSD's business development director said he expects to see more direct-to-consumer advertising this year.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID